STUTTGART, GERMANY — Insilico Biotechnology AG and Meyer Chroma Technology (MCT) announce joining forces to provide the biopharma industry with an eco-system of digital twins enabling integrated predictive process modeling for process development, manufacturing, and product purification.
Insilico has been providing the biopharmaceutical industry with its unique digital twins based platform for the upstream process development and manufacturing since 2018. The Insilico Digital Twins allowed the biopharmaceutical companies to successfully simulate cell culture processes, resulting in robust process development and manufacturing.
Sharing the vision of the smart biofactory, MCT is now joining forces with Insilico to provide the industry with an integrated digital twins based solution for biologics manufacturing and purification. Since its start MCT is providing its customers with its purification digital-twins-based tools. The combined software platform that includes modeling tools for both the upstream and the downstream processes is intended to meet the high demand of the biopharmaceutical companies for a full process modeling of all phases of manufacturing and purification allowing the optimization of the whole process from production in cell culture to subsequent purification. This will result in processes with superior productivity and best-in-class product quality and robustness.
Klaus Mauch, the CEO of Insilico, says: "We are excited to establish our collaboration with MCT, and pleased to offer our customers a comprehensive solution platform that combines MCT experience in the downstream process modeling with Insilico’s upstream modeling tools. This would be an unprecedented step forward towards the full digitization of the biofactory."
Kristian Meyer, CEO of MCT, explains: “This partnership creates new opportunities by linking the core strengths of Insilico and MCT to bring a novel one-stop-shop solution for predictive technologies into the marketplace. This will ultimately enable our customers to build smarter biofactories for biologics production in future.”